1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsUltra-rare Gene-based Therapy (URGenT) Network is sponsored by National Institute of Neurological Disorders and Stroke (NINDS). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NINDS creates the Ultra-Rare Gene-based Therapy (URGenT) Network – IRDiRC NINDS creates the Ultra-Rare Gene-based Therapy (URGenT) Network IRDiRC - News- EIKRA - NINDS creates the Ultra-Rare Gene-based Therapy (URGenT) Network The National Institute of Neurological Disorders and Stroke (NINDS) recently created the Ultra-Rare Gene-Based Therapy ( URGenT) Network.
The URGenT Network supports the development of state-of-the-art gene-based therapies for ultra-rare neurological diseases, which affect as few or fewer than one in fifty thousand people.
It supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders.
It provides funding and resources ( X01 and U01 ) to advance gene-based therapies for ultra-rare neurological diseases from late-stage pre-clinical development into first-in-human clinical testing, to accelerate the development of a promising clinical candidate with robust biological rationale and to demonstrate proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.
With future receipt dates approaching, please feel free to contact NINDS with any questions regarding the program and any interest in submitting an application.
According to the current listing, eligibility includes: Researchers and institutions focused on developing gene-based therapies for ultra-rare neurological diseases are eligible. Clinical trials must have an active Investigational New Drug (IND) designation. Confirm the full requirements in the official notice before applying.
Ultra-rare Gene-based Therapy (URGenT) Network is funded by National Institute of Neurological Disorders and Stroke (NINDS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The AIR program is ARPA-H's most ambitious bet yet: fully autonomous robots that perform stroke-saving thrombectomies without a human surgeon. Proposals are due March 18. A strategic guide for applicants.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read article